18 and older, any sex, with Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final)Primary· 30 days
The percent of treated vessel(s) with ≥ 75% venous thrombus reduction from pre-JETi venogram to final venogram (post-JETi and after any/all adjunctive therapies to treat underlying culprit lesions) via modified Marder score.
Marder Score Reduction is calculated using the formula below: \[(Pre-JETi Marder Score - final Marder Score) / Pre-JETi Marder Score\] x 100.
Modified Marder Score is a calculation based on summation of gradient thrombus burden at the following venous segments: iliac, common femoral, femoral and popliteal. Modified Marder score is based on total score of all imaged and a
Group
Value
95% CI
JETi™ Hydrodynamic Thrombectomy System
84.5
The Primary Safety Endpoint: Composite of JETi-related Major Adverse Events (MAEs) up to 30 DaysPrimary· 30 days
The composite of JETi-related MAEs (death, symptomatic pulmonary embolism (PE), major bleeding, or re-thrombosis of JETi-treated vessel(s) up to 30 days post-JETi procedure for subjects treated for lower extremity DVT and as adjudicated by a CEC
Group
Value
95% CI
JETi™ Hydrodynamic Thrombectomy System
1.7
0.21 – 6.09
Adverse events — posted to ClinicalTrials.gov
Time frame: 30 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
JETi™ Hydrodynamic Thrombectomy System
Serious: 53/116 (46%)
Deaths: 3/116
Serious adverse events (29 terms)
Reaction
System
JETi™ Hydrodynamic Thrombe…
Thrombosis
Vascular disorders
—
Acute Kidney Injury
Renal and urinary disorders
—
Pulmonary Embolism
Respiratory, thoracic and mediastinal disorders
—
Haemorrhage
Vascular disorders
—
Acute Myocardial Infarction
Cardiac disorders
—
Haemoglobin Decreased
Investigations
—
Pneumothorax
Respiratory, thoracic and mediastinal disorders
—
Vascular Stenosis
Vascular disorders
—
Abdominal Pain Upper
Gastrointestinal disorders
—
Gastrointestinal Haemorrhage
Gastrointestinal disorders
—
Intestinal Perforation
Gastrointestinal disorders
—
Retroperitoneal Haematoma
Gastrointestinal disorders
—
Death
General disorders
—
Systemic Inflammatory Response Syndrome
General disorders
—
Urinary Tract Infection
Infections and infestations
—
Fracture
Injury, poisoning and procedural complications
—
Post Procedural Haemorrhage
Injury, poisoning and procedural complications
—
Road Traffic Accident
Injury, poisoning and procedural complications
—
Blood Culture Positive
Investigations
—
Pain In Extremity
Musculoskeletal and connective tissue disorders
—
Endometrial Cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Glioblastoma Multiforme
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Ovarian Cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Rhabdomyosarcoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
The JETi Registry is a prospective, single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the peripheral vasculature. This is a post-market study that will register approximately 280 subjects at approximately 30 centers globally. Subjects participating in this registry will be followed through their 12-month follow up visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06672250 — The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
· recruiting
NCT04649489 — A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate
· Phase 3
· active not recruiting
Other Abbott Medical Devices trials
Trials by the same sponsor.
NCT07421076 — Grid eXplore Mapping Study
· NA
· recruiting
NCT07509658 — TriClip Japan Post-Approval Study
· recruiting
NCT07361445 — Agilis RF TSP Early Feasibility Study
· NA
· recruiting
NCT07373353 — A Clinical Evaluation of AMJ-401
· NA
· recruiting
NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Medical Devices
Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07027878.